Pulse Biosciences, Inc (PLSE) – What Are Brokerages Thinking About This Stock?

Pulse Biosciences, Inc (NASDAQ:PLSE) has received a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $60.20.

PLSE has been the subject of a number of analyst reports. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, September 6th. BTIG Research started coverage on Pulse Biosciences in a report on Wednesday, September 23rd. They issued a “buy” rating and a $70.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, October 15th. Freedom Capital upgraded Pulse Biosciences to a “strong-buy” rating in a report on Wednesday, September 9th. Finally, Oppenheimer boosted their target price on Pulse Biosciences from $35.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 13th.

Insider Buying and Selling at Pulse Biosciences

In other news, COO Liane Teplitsky acquired 1,001 shares of Pulse Biosciences stock in a transaction that occurred on Tuesday, September 1st. The shares were acquired at an average price of $49.95 per share, with a total value of $49,999.95. Following the purchase, the chief operating officer directly owned 4,095 shares of the company’s stock, valued at $204,545.25. The trade was a 32.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have purchased 4,095 shares of company stock valued at $199,931. Company insiders own 74.00% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Several large investors have recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Pulse Biosciences during the second quarter worth $40,672,000. Bank of America Corp DE acquired a new position in shares of Pulse Biosciences in the 2nd quarter valued at $40,115,000. Panoramic Capital LLC acquired a new position in shares of Pulse Biosciences in the 2nd quarter valued at $2,719,000. Bank of New York Mellon Corp acquired a new position in shares of Pulse Biosciences in the 2nd quarter valued at $1,196,000. Finally, Formula Growth Ltd. acquired a new position in shares of Pulse Biosciences in the 2nd quarter valued at $832,000. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Stock Performance

PLSE opened at $52.24 on Friday. The company has a fifty day moving average price of $51.08 and a two-hundred day moving average price of $31.29. Pulse Biosciences has a 52 week low of $12.56 and a 52 week high of $58.90. The firm has a market capitalization of $3.70 billion, a PE ratio of -44.27 and a beta of 1.57.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. Equities analysts forecast that Pulse Biosciences will post -1.34 EPS for the current year.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.